Bionomics Limited (BNO) is a biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (a7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.
Bionomics Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.bionomics.com.au.
This a small cap company with market cap of 202 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how bno dividend grows in the recent years.